MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways
Anne Y Saiki1, Sean Caenepeel, Dongyin Yu
1Department of Oncology Research, Amgen, Thousand Oaks, CA.
Abstract:
While MDM2 inhibitors hold great promise as cancer therapeutics, drug resistance will likely limit their efficacy as single agents. To identify drug combinations that might circumvent resistance, we screened for agents that could synergize with MDM2 inhibition in the suppression of cell viability. We observed broad and robust synergy when combining MDM2 antagonists with either MEK or PI3K inhibitors. Synergy was not limited to cell lines harboring MAPK or PI3K pathway mutations, nor did it depend on which node of the PI3K axis was targeted. MDM2 inhibitors also synergized strongly with BH3 mimetics, BCR-ABL antagonists, and HDAC inhibitors. MDM2 inhibitor-mediated synergy with agents targeting these mechanisms was much more prevalent than previously appreciated, implying that clinical translation of these combinations could have far-reaching implications for public health. These findings highlight the importance of combinatorial drug targeting and provide a framework for the rational design of MDM2 inhibitor clinical trials.
Insights
Combining MDM2 inhibitors with other targeted therapies shows significant promise for overcoming cancer drug resistance. This research identifies synergistic drug combinations for improved cancer treatment strategies.
Area of Science:
- Oncology
- Pharmacology
- Drug Discovery
Background:
- MDM2 inhibitors are promising cancer therapeutics but face challenges with drug resistance as single agents.
- Identifying effective drug combinations is crucial to enhance the efficacy of MDM2 inhibitors.
Purpose of the Study:
- To screen for agents that synergize with MDM2 inhibition to overcome cancer cell resistance.
- To provide a framework for rational clinical trial design involving MDM2 inhibitors.
Main Methods:
- Screening of various agents in combination with MDM2 antagonists.
- Assessment of synergistic effects on cell viability across different cancer cell lines.
Main Results:
- Broad and robust synergy observed between MDM2 inhibitors and MEK or PI3K inhibitors.
- Synergy was independent of specific pathway mutations (MAPK, PI3K) or the targeted node.
- Strong synergy also found with BH3 mimetics, BCR-ABL antagonists, and HDAC inhibitors.
Conclusions:
- Combinatorial targeting of MDM2 with other agents is a viable strategy to circumvent drug resistance.
- These findings have significant implications for public health and the clinical translation of MDM2 inhibitor combinations.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:23Abnormal Proliferation
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:38Mitogens and the Cell Cycle
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...